Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2017-12-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于对外投资设立全资子公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the progress of establishing two wholly-owned subsidiaries. It details the board meeting resolutions, investment amounts, registration completion, and business scope of the new subsidiaries. There are no financial statements, audit opinions, or detailed financial data presented. The document is relatively short (1554 characters) and serves as an update on corporate investment activity rather than a full financial report or regulatory filing. It is not an annual or interim report, nor a call transcript or earnings release. The content fits best with a Capital/Financing Update (CAP) as it concerns investment and establishment of subsidiaries, which is a capital activity update.
2017-12-05 Chinese
关于使用闲置募集资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the use of idle raised funds for cash management by purchasing bank wealth management products. It details the approval process by the board and shareholders, the investment amounts, expected returns, risk analysis, and risk control measures. It also provides a summary of recent transactions involving these funds. The document is relatively short (3132 characters) and does not contain comprehensive financial statements or detailed financial performance data. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR). Instead, it is a specific update on capital management activities related to fundraising proceeds. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is CAP with high confidence.
2017-12-01 Chinese
第二届监事会第十四次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolution from the 14th meeting of the second Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the election of the Supervisory Board Chairman. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory filings beyond the meeting resolution. This fits the category of Board/Management Information (MANG), as it announces changes in company governance structure (election of Supervisory Board Chairman). The document is short and focused solely on this governance matter, not a report or announcement of a report publication.
2017-11-29 Chinese
关于监事辞职及增补职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company regarding the resignation of a supervisory board member and the appointment of a new employee representative supervisor. It includes details about the resignation, legal compliance, and the election of a new supervisor. There are no financial statements, earnings data, or detailed financial analysis. The content focuses on changes in the company's supervisory board members, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or 10-K. Therefore, the appropriate classification is MANG with high confidence.
2017-11-29 Chinese
第二届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the 2nd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the approval of appointments for company vice presidents. It references compliance with company law and stock exchange guidelines. There is no financial data, earnings information, or report publication mentioned. The content focuses on board decisions and management appointments, which aligns with announcements about changes in senior management or board members. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not an Annual Report or Regulatory Filing. Confidence is high due to clear keywords and content focus on board resolutions and management appointments.
2017-11-29 Chinese
关于公司聘任副总裁的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of two new vice presidents at the company. It includes details about the individuals' backgrounds, qualifications, and shareholding status. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content focuses solely on management changes, specifically the hiring of senior executives. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a standalone announcement of management appointments.
2017-11-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.